Mannitol Baxter

Mannitol, the active ingredient in Mannitol Baxter, is an osmotic diuretic presented as an injectable solution for intravenous use. It is employed to lower elevated intracranial and intraocular pressures and to promote diuresis in acute renal failure patients in clinical settings and critical care environments.

GNH USA supplies Mannitol Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, clinics and pharmacies worldwide, and ensures the product meets EU pharmacopeia standards and is available in ready‑to‑use vials.

Mannitol is used as an osmotic agent to manage conditions where fluid shifts reduce pressure or promote diuresis. - Intracranial hypertension: lowers intracranial pressure by drawing fluid from brain tissue into the vascular compartment. - Intraocular hypertension: reduces intraocular pressure in acute glaucoma or ocular surgery. - Acute renal failure: promotes diuresis to facilitate renal clearance of waste products.

Mannitol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal upset after infusion. - Electrolyte disturbances: hyponatremia or hypernatremia. - Transient hypotension: due to rapid plasma expansion.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergy requiring immediate treatment. - Hemolysis: especially in patients with G6PD deficiency. - Pulmonary edema: fluid overload in susceptible patients. - Severe electrolyte imbalance: may cause cardiac arrhythmias.

When using Mannitol, clinicians should observe several safety measures to minimise risks. - Monitor fluid balance: assess input and output closely during therapy. - Check serum electrolytes: especially sodium and potassium levels before and during treatment. - Use caution in heart failure: risk of pulmonary edema from fluid shifts. - Adjust infusion rate in renal impairment: slower administration may be required. - Avoid rapid bolus in patients with intracranial lesions: may cause sudden pressure changes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mannitol can alter the pharmacodynamics or pharmacokinetics of several drugs, necessitating careful review.

Major Interactions (Avoid): - Loop diuretics: additive diuretic effect may cause severe dehydration. - Insulin: hyperosmolar state can impair glucose control, increasing insulin requirements. - ACE inhibitors or ARBs: combined effect may precipitate hypotension.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce renal prostaglandin synthesis, diminishing Mannitol‑induced diuresis. - Aminoglycoside antibiotics: heightened risk of nephrotoxicity. - Anticoagulants: volume expansion may affect coagulation parameters.